Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated health care system. J Manag Care Pharm 2010;16:185–195.
McKee M, Frei BL, Garcia A et al. . Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pract 2011;17:387–394.
Mancini R, Wilson D. A pharmacist managed oral chemotherapy program: an economic and clinical opportunity. Oncology Issues 2012;(Januray/February):28–31.
Holle LM, Puri S, Clement JM. Physician-pharmacist collaboration for oral chemotherapy monitoring: insights from an academic genitourinary oncology practice [published online ahead of print April 21, 2015]. J Oncol Pharm Pract, pii: 1078155215581524.
Wong SF, Bounthavong M, Nguyen C et al. . Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm 2014;71:960–965.
Aldridge VE, Park HK, Bounthavong M, Morreale AP. Implementing a comprehensive, 24-hour emergency department pharmacy program. Am J Health Syst Pharm 2009;66:1943–1947.
Dugan W, McDonald MV, Passik SD et al. . Use of the Zung Self-Rating Depression Scale in cancer patients: feasibility as a screening tool. Psychooncology 1998;7:483–493.
Goodin S, Griffith N, Chen B et al. . Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract 2011;7:7–12.
Safe Storage and Disposal of Cancer Medications. Available at: http://www.cancer.net/navigating-cancer-care/managing-your-care/safe-storage-and-disposal-cancer-medications. Accessed February 8, 2016.
Lee AJ, Boro MS, Knapp KK et al. . Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health Syst Pharm 2002;59:2070–2077.
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed February 8, 2016.
Raschetti R, Morgutti M, Menniti-Ippolito F et al. . Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999;54:959–963.
Howell A, Cuzick J, Baum M et al. . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–62.
Partridge AH, Archer L, Kornblith AB et al. . Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010;28:2418–2422.
Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm 2007;64:2483–2487.
Barnett MJ, Frank J, Wehring H et al. . Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years. J Manag Care Pharm 2009;15:18–31.